Effect of peroxisome proliferator-activated receptor-α siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet

Journal of Hypertension

Volumn 27, Issue 11, 2009, Pages 2223-2231

  Newaz, Mohammad ^a   Ranganna, Katsuri ^a   Truong, Luan D ^b   Oyekan, Adebayo ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; High salt diet; Kidney injury molecule 1; N acetyl glucosaminidase; Peroxisome proliferator activated receptor ; siRNA

Indexed keywords

KIDNEY INJURY MOLECULE 1; MESSENGER RNA; N ACETYL BETA GLUCOSAMINIDASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GENE SILENCING; HEART RATE; HYPERTENSION; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SALT INTAKE;

EID: 73249123240     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328330b6d9     Document Type: Article

References (29)

1. Kliewer SA, Umesomo K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992; 358:771-774.
2. ltoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, et al. Hypertension and insulin resistance: role of peroxisome proliferatoractivated receptor gamma. Clin Exp Pharmacol Physiol 1999; 26:558-560.
3. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator activated receptors (PPARs): tissue distribution of PPARα, β, and γ in the adult rat. Endocrinology 1996; 137:354-366. (Pubitemid 26005011)
4. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129:823-834. (Pubitemid 30142890)
5. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth muscle cells is inhibited by PPAR-α but not PPAR-gamma activators. Nature 1998; 393:790-793. (Pubitemid 28299490)
6. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Praia AD. Etomoxirinduced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 278:F667-F675. (Pubitemid 30215246)
7. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferatoractivated receptor-α and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension 2001; 38:249-254.
8. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α- mediated cardiovascular effects. Mutat Res 2005; 579:163-171. (Pubitemid 41540140)
9. Oyekan AO, Newaz MA, Blanton A, Fidelis P. Transcription factors and their contribution to DOCA/salt hypertension. In: e Silva JM, Saldanha C, Oliveira V, Prie A, Shore A, editors. Proceedings of 23rd European Conference on Microcirculation 2004. pp. 121-126.
10. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPAR{α} activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40:866-871. (Pubitemid 35434908)
11. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR α activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J MoI Cell Cardiol 2004; 36:295-304. (Pubitemid 38202358)
12. Newaz MA, Ranganna K, Oyekan AO. Relationship between PPARα activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol 2004; 6:1-9. (Pubitemid 38729276)
13. Tabernero A, Schoonjans C, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator activated receptor α protects against myocardial ischemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002; 2:1-10.
14. Mattson DL, Meister CJ, Marcelle ML. Dietary protein source determines the degree of hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2005; 45:736-741.
15. Schiffrin EL, Lariviere R, Li LS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 1996; 33:235-248. (Pubitemid 26164473)
16. Oyekan AO, McAward K, McGiff JC. Endothelin-1 and cytochrome P450 arachidonate metabolites interact to promote tissue injury in DOCA/salt Hypertension. Am J Physiol 1999; 276:R766-R775.
17. Vaskonen T, Mervaala E, Krogerus L, Teräväinen TL, Laakso J, Karppanen H, Vapaatalo H. Cardiovascular effects of chronic inhibition of nitric oxide synthesis and dietary salt in spontaneously hypertensive rats. Hypertens Res 1997;20:183-192.
18. Vieira JM Jr, Rodrigues LT, Mantovani E, Dellê H, Mattar AL, Malheiros DM, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol 2005; 101:82-91. (Pubitemid 41547103)
19. Bonventre JV. Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 2008; 241:78-83. (Pubitemid 351883663)
20. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in the urinary tract of rabbits and humans. Am J Physiol 1997; 273:F1013-F1022. (Pubitemid 127752137)
21. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73:863-869.
22. Wesseling S, Joles JA, van Goor H, Bluyssen HA, Kemmeren P, Holstege FC, et al. Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats. Physiol Genomics 2007; 28:158-167. (Pubitemid 46705403)
23. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115:518-533. (Pubitemid 46184203)
24. Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, Kroetz DL. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Proc Soc Exp Biol Med 1999; 221:32-38. (Pubitemid 29203365)
25. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-{α} activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 2005; 46:366-371. (Pubitemid 41099171)
26. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL Peroxisome proliferator-activated receptor-{α} and receptor-{gamma} activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42:737-743. (Pubitemid 37237318)
27. Tordjman K, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, et al. Absence of peroxisome proliferator-activated receptor-α abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension 2007; 50:945-951. (Pubitemid 350287539)
28. Subramanian S, DeRosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, et al. PPAR(α) activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab 2006; 291 :E1365-E1371. (Pubitemid 44904046)
29. Yagil C, Yagil Y. Peroxisome proliferator-activated receptor-α: friend or foe? Hypertension 2007; 50:847-850. (Pubitemid 350287524)